
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Treatment of vitiligo has advanced significantly in recent years with the use of topical immunomodulators and newer forms of phototherapy, Pearl F. Grimes, M.D., said.






